Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Leases (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Current Leases readings, the most recent being $7.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 4.95% year-over-year to $7.1 million, compared with a TTM value of $7.1 million through Dec 2025, up 4.95%, and an annual FY2025 reading of $7.1 million, up 4.95% over the prior year.
  • Current Leases hit $7.1 million in Q4 2025 for Apellis Pharmaceuticals, up from $7.0 million in the prior quarter.
  • The five-year high for Current Leases was $7.4 million in Q2 2025, with the low at $3.9 million in Q1 2021.
  • Median Current Leases over the past 5 years was $5.8 million (2023), compared with a mean of $5.8 million.
  • The sharpest move saw Current Leases soared 51.46% in 2021, then increased 3.39% in 2025.
  • Year by year, Current Leases stood at $4.1 million in 2021, then surged by 36.7% to $5.6 million in 2022, then increased by 14.51% to $6.4 million in 2023, then increased by 4.84% to $6.8 million in 2024, then rose by 4.95% to $7.1 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $7.1 million, $7.0 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.